Codexis Inc (CDXS) Stock Price, Quote & News

Company Profile

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with A...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 421 8100

Website: www.codexis.com

Address:

200 Penobscot Drive, Redwood City, United States

djohndjohn Nov. 14 at 9:12 PM

$CDXS Jdnguy wouldn't that make $1.64 a major selling opportunity? Silly stuff LOL

0 · Reply

Jdnguyen24 Nov. 14 at 7:37 PM

$CDXS next potential major buying opportunity may be if Fed doesn’t cut rate in Dec. microcap index will get slammed because of the assumption most companies are leveraged and CDXS has solid balance sheet.

0 · Reply

HedgeAlerts Nov. 14 at 5:58 PM

Hedge Alert Live - Protect Your Portfolio Contract: $CDXS $2.50 Put · NOV 21, 2025 Exp Entry Price: $0.73 - $1.30 Exit Price Target: $1.62 Profit Margin: +122% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

djohndjohn Nov. 14 at 12:41 PM

$CDXS Actually in looking at bios Alison Moore has a lot of experience in drug manufacturing and doesn't Dilly. Dilly has zero manufacturing experience! Moore 25+years. including an extensive background in biomanufacturing! 20 years in manufacturing roles at Amgen. And manufacturing roles at Genentech. Could be the reason for CEO switch? Dilly only knows how to move drug candidates through FDA approval. Moore knows how to build a CDMO!

1 · Reply

LiquidThetaOptions Nov. 14 at 12:25 PM

💎 LiquidTheta® Live Actionable Trade Asset: $CDXS Contracts: $CDXS June 18, 2026 $2 Calls Scale in: $0.47- $0.58 Scale out: $1.84-$3.15 Profit Potential : 240% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

HedgeAlerts Nov. 14 at 7:18 AM

Hedge Alert Live - Protect Your Portfolio Contract: $CDXS $2.50 Put · NOV 21, 2025 Exp Entry Price: $0.73 - $1.40 Exit Price Target: $1.65 Profit Margin: +126% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Jdnguyen24 Nov. 14 at 5:21 AM

$CDXS $37.8 million “Supply Assurance Agreement” 10-Q / subsequent events note, Codexis states: “Pursuant to the terms of the agreement, we are entitled to receive a one-time non-refundable and non-creditable payment of $37.8...” meaning they receives cash regardless of further performance by Merck Supply assurance: is a commitment they to supply a given enzyme (or set of enzymes) for Merck’s manufacturing needs.

0 · Reply

Jdnguyen24 Nov. 14 at 5:04 AM

$CDXS 40 qualified prospects broken out between their GMP facility and Nitto Denko. They can still make a significant amount more vs commoditized enzymes with Ligase contract($3-10M); Eco-platform contracts($1-20M) from Phase 1 - 3 before commercialization to achieve break even cash flow. Commercialization with use of Eco-Platform start to commercialization ($20-50M) pending on how large the drug indication drug is among patients. Let’s say $50M more revenue needed to break even with 2024 total expenses at $118M and they hit $70M revenue for 2025. 10 contracts @ $5M/each doable on low end for 2026 of 40 qualified prospects? Or 15 contracts $3-5M/each? If they do break even, market will start buying more aggressively after Q3 2026 earnings if they confirm Q4 will meet or exceed break even reasonable estimation?

0 · Reply

Jdnguyen24 Nov. 14 at 4:50 AM

$CDXS 2022 was Codexis’s highest-revenue year: about $138.6 million; all-time high stock price was $41.78, 11/8/21. 2024 total expenses $118M. High end 2025 revenue projection $68M, may exceed to $70M? Based off past presentations and SEC filings: ECO Synthesis / platform evaluation / early-access agreements • Typical range: • Evaluation / early access: $0.1M – $2M (engineering/testing fees, evaluation payments) •Commercial platform license / commercialization: $10M – $100M+ (upfront + multi-phase milestones + royalties), depending on breadth of license and customer scale. •Phase-based development milestone buckets (when deals are structured by clinical phase) • Phase 1: small technical milestone(s): $0.5M – $5M • Phase 2: moderate milestone(s): $2M – $15M • Phase 3: larger milestone(s): $10M – $50M • Commercialization / launch milestones + royalties: $10M – $100M+ plus royalties (highly variable) • Ligase $5-10M/each/Big Pharma

0 · Reply

Jdnguyen24 Nov. 14 at 4:27 AM

$CDXS For profitable bio-industrial / biological-producer companies (i.e., companies that make enzymes, biologics, or other bio-manufactured products): a likely EV/EBITDA multiple on exit (sale) is around 12×–16×, based on the TranzDigi data for similar companies.

0 · Reply

Codexis Announces Signing of Lease for GMP Manufacturing Facility

Nov 7, 2025, 2:16 PM EST - 7 days ago

Codexis, Inc. (CDXS) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 9:58 AM EDT - 16 days ago

Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing

Oct 23, 2025, 7:05 AM EDT - 22 days ago

Codexis to Report Third Quarter 2025 Financial Results on November 6

Aug 28, 2025, 9:00 AM EDT - 2 months ago

Codexis to Participate in Cantor Global Healthcare Conference

Aug 13, 2025, 7:57 PM EDT - 3 months ago

Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:05 PM EDT - 3 months ago

Codexis Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 3 months ago

Codexis to Report Second Quarter 2025 Financial Results on August 13

May 22, 2025, 7:00 AM EDT - 6 months ago

Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

May 21, 2025, 4:05 PM EDT - 6 months ago

Codexis to Participate in Jefferies Global Healthcare Conference

May 14, 2025, 6:50 PM EDT - 6 months ago

Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:05 PM EDT - 6 months ago

Codexis Reports First Quarter 2025 Financial Results

May 7, 2025, 7:00 AM EDT - 6 months ago

Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

Apr 30, 2025, 4:05 PM EDT - 7 months ago

Codexis to Report First Quarter 2025 Financial Results on May 14

Apr 9, 2025, 5:00 PM EDT - 7 months ago

Codexis Announces Byron Dorgan to Retire from Board of Directors

Mar 7, 2025, 4:05 PM EST - 9 months ago

Codexis Announces New Employment Inducement Grants

Feb 27, 2025, 10:20 PM EST - 9 months ago

Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 4:05 PM EST - 9 months ago

Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th

Feb 6, 2025, 4:05 PM EST - 10 months ago

Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

Jan 16, 2025, 4:05 PM EST - 10 months ago

Codexis Appoints Christos Richards to Board of Directors

Nov 19, 2024, 4:05 PM EST - 1 year ago

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 4:05 PM EST - 1 year ago

Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics

Nov 12, 2024, 4:05 PM EST - 1 year ago

Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors

Nov 11, 2024, 4:05 PM EST - 1 year ago

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

Nov 4, 2024, 4:05 PM EST - 1 year ago

Codexis to Participate in Upcoming Healthcare Conferences

Oct 31, 2024, 10:48 PM EDT - 1 year ago

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 4:05 PM EDT - 1 year ago

Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting

Oct 10, 2024, 4:05 PM EDT - 1 year ago

Codexis to Report Third Quarter 2024 Financial Results on October 31

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company

Oct 1, 2024, 7:05 AM EDT - 1 year ago

Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences

Aug 20, 2024, 4:05 PM EDT - 1 year ago

Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting

Aug 15, 2024, 4:05 PM EDT - 1 year ago

Codexis Publishes FY2023 Sustainability Disclosures

Aug 8, 2024, 11:01 PM EDT - 1 year ago

Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript

Jul 18, 2024, 4:05 PM EDT - 1 year ago

Codexis to Report Second Quarter 2024 Financial Results on August 8

Jul 1, 2024, 4:05 PM EDT - 1 year ago

Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets

May 20, 2024, 4:05 PM EDT - 1 year ago

Codexis to Participate in TD Cowen 2nd Annual Sustainability Week

May 14, 2024, 6:00 AM EDT - 1 year ago

Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting

May 2, 2024, 8:24 PM EDT - 1 year ago

Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript

Apr 18, 2024, 4:05 PM EDT - 1 year ago

Codexis to Report First Quarter 2024 Financial Results on May 2

Apr 11, 2024, 7:05 AM EDT - 1 year ago

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

Feb 28, 2024, 10:39 PM EST - 1 year ago

Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 4:05 PM EST - 1 year ago

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Feb 26, 2024, 4:05 PM EST - 1 year ago

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche

Feb 26, 2024, 8:05 AM EST - 1 year ago

Codexis to Participate in TD Cowen 44th Annual Health Care Conference

Feb 20, 2024, 8:05 AM EST - 1 year ago

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Feb 14, 2024, 4:05 PM EST - 1 year ago

Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28

Feb 13, 2024, 4:05 PM EST - 1 year ago

Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones

Feb 1, 2024, 4:05 PM EST - 1 year ago

seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting

Dec 27, 2023, 8:30 AM EST - 2 years ago

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

Dec 13, 2023, 4:06 PM EST - 2 years ago

Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase

djohndjohn Nov. 14 at 9:12 PM

$CDXS Jdnguy wouldn't that make $1.64 a major selling opportunity? Silly stuff LOL

0 · Reply

Jdnguyen24 Nov. 14 at 7:37 PM

0 · Reply

HedgeAlerts Nov. 14 at 5:58 PM

0 · Reply

djohndjohn Nov. 14 at 12:41 PM

1 · Reply

LiquidThetaOptions Nov. 14 at 12:25 PM

0 · Reply

HedgeAlerts Nov. 14 at 7:18 AM

0 · Reply

Jdnguyen24 Nov. 14 at 5:21 AM

0 · Reply

Jdnguyen24 Nov. 14 at 5:04 AM

0 · Reply

Jdnguyen24 Nov. 14 at 4:50 AM

0 · Reply

Jdnguyen24 Nov. 14 at 4:27 AM

0 · Reply

buymoremakemore Nov. 14 at 3:44 AM

$CDXS ive made 700k almost 800k net gain this year. I am down $22,000 on this ticker with average @$2.28. I feel for those with a higher average and are bummed they might not get that back for a while or fear they might not ever. But being a whining bagholder on here gets you nowhere. Several of us have the financial means and patience for management to execute their plan. Im waiting at least a year before considering selling. We know Q4 will be good. And more clients are on the way. I think theres a good chance this gets bought out next year. Give it time

1 · Reply

Jdnguyen24 Nov. 14 at 3:09 AM

$CDXS I’m being very greedy on share accumulation while the market is very fearful. They have next to nil debt on their balance sheet and if Merck is investing a $38M cash infusion into them to cover any additional expenses an extra year, I would say it’s a very significant sign of confidence for this microcap. Their historical relationship: Enzyme Supply for Sitagliptin (Januvia / Janumet) • Codexis developed a proprietary enzyme (via the CodeEvolver platform) that Merck uses in the manufacturing of sitagliptin, the active pharmaceutical ingredient (API) in Merck’s diabetes drugs Januvia and Janumet. • They first entered a supply agreement in 2012, and in 2015 extended that contract. • In 2021, the agreement was extended again: Codexis will supply the enzyme through December 31, 2026, with a possible additional 5-year renewal by mutual agreement.

1 · Reply

Fingerlickengood Nov. 14 at 2:45 AM

$CDXS I don't think their tech is proprietary, and that's a problem!

1 · Reply

Jdnguyen24 Nov. 14 at 2:43 AM

$CDXS I recall on one of the past investment banking healthcare conference calls, Dilly had called out ~5 of their major global competitors acknowledging the limitations of each company’s abilities using a similar platform to them but unable to meet the challenges of very complex molecules needed by Pharma that they are able to tackle. If we look at Paxlovid as an example, they had been asked on an earnings call if they would be producing any enzymes for the vaccine and initially they said no, but lo and behold in a following earnings call, they ended up supplying enzymes in a very tight time frame for Paxlovid. Patience Longs.

0 · Reply

Jdnguyen24 Nov. 14 at 2:42 AM

$CDXS or until they have track record over next 5-10yrs. It will just be the beginning of higher demand by 2030. ~6 current approved sIRNA therapeutics most for smaller indications of rare diseases with the exception of Inclisirin. Once some Phase 3 sIRNA therapeutic drugs get approved CDXS will come into more significant play with the help of Nitto Denko for the larger indications and for the early stage deals it will be with their own GMP facilities(fees, equity stake, royalties). sIRNA therapeutics will be a major breakthrough since a patient would only need to take their medication 2x/yr & no longer need to worry about bloodwork, negative impact of medication on kidneys, etc.

0 · Reply

Jiggitus23 Nov. 13 at 11:29 PM

$CDXS did something happen today? I don't understand why everyone turned into negative nancies

1 · Reply

buymoremakemore Nov. 13 at 10:10 PM

$CDXS I guess theyre just setting up the infrastructure to get bought out. Hence going at GMP alone. Still believe $5 BO possible or 500M but wont be surprised by 350M BO. This is unproven tech at large sce but most people know ittl work but without being proven CDXS has less leverage. I know people wish the potential BO could be bigger given how much potential SiRNA has but its better than a company with a shit reputation that nobody want’s to buy.

1 · Reply

Bondra Nov. 13 at 8:07 PM

$CDXS Just buy this dog Jesus christ

0 · Reply

Winner111 Nov. 13 at 8:07 PM

$CDXS i sold this shit before its too late, goodluck guys.

0 · Reply

Fingerlickengood Nov. 13 at 7:42 PM

$CDXS Bad signal to investors when a CEO makes more in salary, pension and stock awards than he /she did in new contract/licensing deals before stepping aside! Just saying!

0 · Reply

Camille65 Nov. 13 at 7:28 PM

$CDXS

2 · Reply

Fingerlickengood Nov. 13 at 7:25 PM

$CDXS I think going it alone on the GMP facility spoke volumes!

1 · Reply

Market Cap	174.33M
Revenue (ttm)	59.35M
Net Income (ttm)	-65.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-109.99%
Debt to Equity Ratio	1.03

Volume	1,409,236
Avg Vol	833,514
Day's Range	N/A - N/A
Shares Out	90.32M
Stochastic %K	3%
Beta	2.57
Analysts	Strong Sell
Price Target	$6.75